Malignancy as a complication of immunosuppressive therapy.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000917:Antibody Formation / Q000187:drug effects; D000951:Antigens, Neoplasm / Q000302:isolation & purification* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000276:immunology; D002051:Burkitt Lymphoma / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006087:Graft vs Host Reaction; D006649:Histocompatibility Antigens; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D066298:In Vitro Techniques; D007668:Kidney / Q000276:immunology; D007938:Leukemia / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D008748:Methylcholanthrene / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000209:etiology* / Q000276:immunology; D009447:Neuroblastoma / Q000276:immunology; D009858:Oncogenic Viruses / Q000276:immunology; D012516:Osteosarcoma / Q000276:immunology; D011817:Rabbits; D013601:T-Lymphocytes / Q000187:drug effects; D014181:Transplantation Immunology
D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D006649:Histocompatibility Antigens; D007166:Immunosuppressive Agents; D008748:Methylcholanthrene; D003520:Cyclophosphamide